Sean Hall

MD, MBA, LTA, PhD

Chief Executive Officer & Chairman, Medlab Group Inc.

Dr. Sean Hall is a proven innovator and commercial leader in biotechnology and life sciences, with more than 25 years of experience advancing breakthrough healthcare solutions from concept to global markets. As CEO and Chairman of Medlab Group Inc., he drives the strategic development and commercialisation of advanced therapeutics, drug delivery technologies, and nutraceutical innovations.

Dr. Hall is recognised for co-creating the NanoCelle® nanoparticle delivery system, the world’s first scalable platform of its kind, and for advancing NRGBiotic®, a clinically validated probiotic adjunct for depressive disorders. Under his leadership, Medlab has achieved significant milestones, including pioneering novel pain research programs, building a global reputation for quality research, innovation and new treatment advocacy, and securing more than 45 patents across drug delivery and microbiome science.

A seasoned executive, Dr. Hall has successfully navigated complex FDA, EMA, and TGA regulatory pathways, raised significant capital through government incentives and international partnerships, and guided Medlab’s readiness for a US IPO. His portfolio of peer-reviewed publications, international patents, and published works underscore his ability to transform research into scalable, revenue-generating assets.

With a track record of aligning scientific innovation to market opportunities, Dr. Hall continues to position Medlab Group at the forefront of global healthcare innovation and investor value creation.